Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBio-4101 in Relapsed or Refractory Melanoma
NCT05628883Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tidal-01 in melanoma, sponsored by Moffitt Cancer Center. Primary endpoint: Percentage of Participants that Successfully Receive TBio-4101 at Day 7. Started Nov 2022; status: completed.
02
Drugs
tidal-01
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05628883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05628883.